Meletios A. Dimopoulos, MD, discussed where bispecific antibodies such as teclistamab may fit for patients with relapsed Waldenström macroglobulinemia.
|Videos|June 8, 2017
Novel Prostate Cancer Risk Classifier Highly Prognostic for Metastases
Author(s)Daniel Eidelberg Spratt, MD
This video highlights a clinical-genomic risk classification system that is highly prognostic for distant metastasis and more accurate than clinical risk assessments.
Advertisement
In this video, Daniel Eidelberg Spratt, MD, of the University of Michigan, discusses how the use of a readily available genomic classifier combined with clinicopathologic variables can generate a simple to use clinical-genomic risk classification system that is highly prognostic for distant metastasis and more accurate than clinical risk assessments.
Spratt presented results of the study (
Advertisement
Related to this article
In the LINKER-SMM1 trial, single-agent linvoseltamab produced a 100% overall response rate among evaluable patients with high-risk smoldering multiple myeloma.
David R. Gandara, MD, explains what makes KRAS G12C biologically distinct from other KRAS subtypes in NSCLC immunotherapy response.
Peter Forsyth, MD, discusses a first-in-human trial of intrathecal dendritic cell therapy for leptomeningeal disease from breast cancer.
Adding radiotherapy to tislelizumab and chemotherapy also appeared to prolong progression-free survival in a real-world setting.
![“[E]ven if patients relapse following an allogeneic transplant, donor lymphocyte infusions can be incredibly helpful,” said Mary Jo Lechowicz, MD.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/06df696db42b151710c58727b1333ee098de6453-1200x800.jpg?w=350&fit=crop&auto=format)
“[E]ven if patients relapse following an allogeneic transplant, donor lymphocyte infusions can be incredibly helpful,” said Mary Jo Lechowicz, MD.
At SOHO 2026, experts highlighted new findings and advances across diseases including lymphoma, myelodysplastic syndrome, and leukemia.
Poster sessions at WCLC 2026 detail how surgery, nursing, and pathology can contribute to the multidisciplinary care of patients with lung cancer.